Relation and GSK join forces to advance fibrotic diseases and ...
Dec 10, 2024 · Big pharma company GSK and UK AI-biotech Relation Therapeutics have entered into two strategic collaborations to identify and validate new therapeutic targets for osteoarthritis and fibrotic diseases. Under the terms of the two agreements, GSK will make an upfront payment of $45 million to Relation ...
Amgen: Phase 2 results for GLP-1-GIP weight loss drug
Nov 28, 2024 · A number of different drugs, such as Novo Nordisk’s Ozempic, target either the GLP-1 or GIP receptor. Like Eli Lilly’s Mounjaro/Zepbound (tirzepatide), MariTide targets both receptors simultaneously, thereby having a stronger weight loss effect, as suggested by preclinical studies.Next to the dual mechanism of action, the antibody-peptide combination also gives the drug a longer half-life ...
How will the Biosecure Act impact the pharma industry?
Oct 8, 2024 · But what does the Act mean for the biotech and pharma industry and how can companies best prepare for any impacts on future business? The Biosecure Act was first proposed by the US government late last year due to concerns about national security and how genetic and other biological data could be misused by foreign adversarial governments with a focus on China.
Astellas licenses AviadoBio’s dementia gene therapy candidate
Oct 10, 2024 · “This strategic collaboration will combine our promising gene therapy candidate for FTD-GRN and delivery expertise with Astellas’ global capabilities in development and commercialization of gene therapies.
AbbVie acquires Aliada Therapeutics in $1.4bn deal
Oct 30, 2024 · Based in Boston, US, Aliada Therapeutics was founded in 2021 by Johnson & Johnson together with venture capital firm RA Capital Management. The company’s MODEL platform was originally created at Johnson & Johnson and licensed to Aliada when it was created.
The top 5 CDMOs developing advanced therapies
Jul 18, 2024 · Headquarters: Somerset, New Jersey, US. Founded: 2007. Catalent was set up when Blackstone acquired the pharmaceutical and services assets from Cardinal Health and rebranded them under their current name.. Catalent handles the production and supply of therapeutic products across the range of small molecules and biologics.
BMS achieves FDA approval for schizophrenia drug Cobenfy
Oct 1, 2024 · Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity value that completed earlier this year. The deal has paid off as Karuna’s lead asset was approved last week by the US FDA.. Cobenfy is a combination of xanomeline, which acts on the muscarinic receptor system by activating it and trospium, which blocks the muscarinic ...
Spyre Therapeutics: Phase 1 trials for extended half-life IBD therapy
Dec 3, 2024 · The U.S. biotech company Spyre Therapeutics announced yesterday that it has dosed the first participants in two Phase 1 trials testing its first-generation anti-TL1A antibodies, SPY002-091 and SPY002-072, for the treatment of inflammatory bowel disease (IBD).
Archives - October 3, 2024 - Biopharma-Reporter.com
Oct 3, 2024 · The UK cell therapy biotech will now advance its first candidate cell therapy to clinical trials for treatment of liver disease.
GE Healthcare Life Sciences completes transition into Cytiva
Apr 1, 2020 · In the one of the largest deals seen in the contract development and manufacturing organization (CDMO) sector, Danaher Corporation decided to spend $21.4bn (€19.5bn) to acquire GE Healthcare Life Sciences.. Now, with the deal complete, GE Healthcare Life Sciences has emerged at the other side rebranded as Cytiva.